Background: Radial lines in the cheek area can be associated with an older and less attractive appearance. In a prospective, open-label study (the BEAM study), we evaluated the effectiveness of Juvéderm ® Volift ™ (VYC-17.5L)-a hyaluronic acid-based filler with lidocaine developed using Vycross ® technology-for treating the deep skin depressions of dynamic radial cheek lines. The study combined objective clinical effectiveness measures with subjective lay assessments of the effect of VYC-17.5L treatment on perceived age and attractiveness. Methods: A sample of 53 French women aged 40 to 65 years received VYC-17.5L treatment in both cheeks on Day 1 with optional touch-up treatment on Day 14. Effectiveness of treatment was evaluated on Day 45. Median total injection volumes of 4.0 mL and 2.0 mL were used for initial and touch-up treatment with VYC-17.5L, respectively. The primary endpoint was subject-assessed overall aesthetic improvement in dynamic radial cheek lines when smiling using the Global Aesthetic Improvement Scale (GAIS). Secondary endpoints included evaluating investigator assessments of improvement in dynamic radial cheek lines using the GAIS, subject Self-Perception of Age (SPA), subject assessments of treatment satisfaction and natural look of treated areas, and instrument-assessed changes in roughness, amplitude, and texture of radial cheek lines (DermaTOP ® ). Additional analyses evaluated changes in skin quality measures (skin hydration [MoistureMeterD ® ], skin elasticity/firmness [Cutometer ® ], and skin density/thickness [DermaScan ® C]). Information on perceived age and attractiveness was collected from panels of German lay evaluators (mean age, 23.2 years) who viewed photographs and videos of subjects taken before treatment and on day 45. Separate panels of German lay evaluators evaluated videos of subjects recorded either before or after treatment to assess treatment noticeability. Safety assessments included injection site responses (ISRs). Results: On Day 45, 98% of subjects reported their radial cheek lines were much improved or improved on GAIS, and independent investigators rated 95% of subjects as responders. Subjects who perceived themselves as the same age or older versus their current age before treatment (n=38) perceived themselves on average as 2.0 years and 5.5 years younger, respectively, after treatment. Mean satisfaction and natural look of treated areas on Day 45 was 7.9 and 7.2 out of 10, respectively. Static and dynamic radial cheek lines were significantly improved with respect to roughness, amplitude, and texture measures after treatment compared with baseline (P<0.001). VYC-17.5L treatment significantly improved skin water content (P<0.0001), elasticity/firmness (P<0.05), and dermis density (P<0.0001) versus baseline, with no significant change in overall thickness. In the photo review, lay assessors judged faces as significantly younger after treatment (P<0.001), with perceptions of attractiveness remaining unchanged. A smaller proportion of treated faces was identified correctly compared with untreated faces in the video review of treatment noticeability (P<0.001). The most commonly reported ISRs were hematoma (35.9%), bruising (30.2%), and mass (22.6%); most ISRs were mild and resolved within 15 days. No serious adverse events were reported. Conclusions: VYC-17.5L is effective for correcting dynamic radial cheek lines, with 98% of subjects reporting improvement 45 days after treatment. Treatment resulted in instrument-assessed improvements in skin quality and perception of younger age as evaluated by subjects and independent assessors. In addition, lay assessments suggest that treatment with VYC-17.5L was not noticeable enough to allow independent observers to reliably identify treated versus untreated faces.
INTRODUCTION
• Facial appearance, including skin condition, affects perceptions of a person's age, health, and attractiveness, and facial aesthetic treatment can improve confidence and self-esteem 1,2 • Injectable hyaluronic acid (HA) gels may be used to correct wrinkles and folds in the cheeks, known as "smile lines" or radial cheek lines, which can extend from the periorbital area to the masseter region 2 • VYC-17.5L (Juvéderm ® Volift ™ ; Allergan plc, Dublin, Ireland), an HA-based filler indicated for the treatment of deep skin depressions due to conditions such as premature aging, was developed using Vycross ® technology (Allergan plc, Dublin, Ireland), which combines low-and high-molecular-weight HA to improve the crosslinking efficiency of the HA chains; the tightly crosslinked HA network yields a higher viscosity gel with greater lift capacity and improved response durability 3 • The purpose of this study was to evaluate the effectiveness of VYC-17.5L treatment of dynamic radial cheek line skin depressions
METHODS

Study Design
• A prospective, uncontrolled, open-label study conducted at a single site in France evaluated the effectiveness of VYC-17.5L for treating dynamic radial cheek lines (ANSM registration number 2016-A00909-42) • VYC-17.5L treatment was administered to subjects in both cheeks on Day 1 with optional touch-up treatment on Day 14; follow-up occurred through Day 45 after initial treatment
Subjects
• Women aged 40 to 65 years • Inclusion criteria ─ Allergan Fine Lines Scale score ≤3 (5-point scale: 0=none, 1=minimal, 2=moderate, 3=severe, 4=diffuse) 4 ─ Agreement to refrain from facial skin-care regimen changes and antiwrinkle, filler, or skin resurfacing procedures or treatments during the study • Exclusion criteria ─ Anticoagulant therapy during, 10 days before, or 3 days after study treatment ─ Anti-inflammatory drugs or substances that increase coagulation time 10 days before or 3 days after study treatment ─ Facial surgery, tissue grafting, or tissue augmentation with silicone, fat, or other permanent or semi-permanent dermal fillers during the study; temporary facial dermal filler injections within the year before the study
Analyses
Primary Endpoint
• Subject-assessed overall aesthetic improvement from baseline (Day 1) to Day 45 in dynamic radial cheek lines while smiling, using the Global Aesthetic Improvement Scale (GAIS; 2=much improved, 1=improved, 0=no change, −1=worse, −2=much worse)
Secondary Endpoints
• Investigator-assessed improvement in dynamic radial cheek lines from baseline to Day 45 using the GAIS ─ Subjects achieving a GAIS score of 1 or 2 (improved or much improved) for both cheeks were classified as responders by investigators; partial responders were those with a GAIS score of 1 or 2 for only 1 cheek; non-responders were those with a GAIS score ≤0 for both cheeks • The order of each subject's before and after images was randomized, and evaluators were asked to indicate which face they considered to be younger looking, healthier, and more attractive ─ Lay evaluator assessments of treatment noticeability during a review of videos of subjects smiling either before or after treatment
Safety
• Injection site responses (ISRs) and adverse events (AEs) monitored by investigators
Statistics
• Quantitative variables summarized descriptively (i.e., mean, median)
• Paired t-test or Wilcoxon signed rank test for significance of changes from baseline
RESULTS
Subjects
• Subjects were French women, most with Fitzpatrick skin phototypes II and III ( aOne subject was lost to follow-up after Day 1, resulting in a total of 52 subjects who received treatment and were included in the effectiveness analyses. The safety population included all 53 subjects. bThere were no subjects with Fitzpatrick skin phototypes I, V, and VI. 
Subject Rating Investigator Ratinga
Improved Much Improved
GAIS Score
aFor both cheeks in 52 subjects. GAIS, Global Aesthetic Improvement Scale (2=much improved; 1=improved; 0=no change; −1=worse; −2=much worse).
Self-Perception of Age
• There was a 2-fold increase in the proportion of subjects who reported looking younger following VYC-17.5L treatment (Figure 2) • Subjects who perceived themselves as the same age or older than their current age at baseline (n=38) perceived themselves on average as 2.0 years and 5.5 years younger, respectively, after treatment Ratings based on a 10-point scale (0=not at all, 10=very much).
Instrument-Assessed Changes in Wrinkle Parameters
• Static and dynamic radial cheek lines significantly improved with respect to roughness, amplitude, and texture measures at Day 45 after treatment vs baseline (P<0.001 for all comparisons) ─ Figure 4 shows improvements from baseline to Day 45 in roughness, amplitude, and texture through minimized skin depressions/creases, increased smooth areas, and less pronounced raised areas/bumps
Analysis of Skin Quality Measures
• Treatment with VYC-17.5L significantly improved skin hydration, elasticity/firmness, and density over baseline, with no significant change in overall thickness ( 
Independent Lay Panel Reviews
• A total of 550 lay evaluators (mean age, 23.2 years) assessed the age, health, and attractiveness of subjects in photographs and videos ─ Those who viewed photographs of subjects at baseline and Day 45 judged faces as significantly younger after treatment (P<0.001), with perceptions of attractiveness remaining unchanged ( Table 3 ) ─ Women evaluators were more likely than men to view images after treatment as younger than before treatment (P<0.05) ─ Women evaluators were more likely than men to judge subjects in post-treatment videos as more attractive (P<0.05) • Lay evaluators who assessed the noticeability of subjects' treatment correctly identified a smaller proportion of treated vs untreated faces in the video review (P<0.001) • These lay assessments suggest that treatment with VYC-17.5L results in natural-looking outcomes, as independent observers were unable to consciously discern treated vs untreated faces; Figure 5 shows representative examples of subjects before and after images viewed by independent lay evaluators
Safety Evaluation
• ISRs were reported by 33 of 53 subjects, with the most common being hematoma, bruising, and mass, and most being mild in severity ( 
CONCLUSIONS
• VYC-17.5L is effective for correcting dynamic radial cheek lines, with 98% of subjects reporting improvement on Day 45
• Treatment with VYC-17.5L led to significant improvements in instrumentassessed wrinkle parameters and skin quality
• Subjects who had been treated with VYC-17.5L in their radial cheek lines were independently assessed as younger looking and perceived themselves as younger looking
• Despite statistically significant effects of VYC-17.5L treatment on age ratings, independent observers were unable to consciously discern treated vs untreated faces; these findings suggest that treatment with VYC-17.5L can yield natural-looking outcomes
• VYC-17.5L demonstrated an acceptable safety profile for the treatment of radial cheek lines, with ISRs mostly mild and as expected
